Erectile Dysfunction (ED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Erectile Dysfunction (ED) refers to the recurrent and persistent inability, either partial or complete, to achieve or maintain an erection firm enough for satisfactory sexual intercourse, even when proper erotic stimuli are present. This condition is recognized as a social problem affecting men of various age groups and ethnicities, significantly impacting the quality of life (QoL) for the affected individual and their partner. ED involves two primary aspects of male erection: reflex erection and psychogenic erection, both of which can be targeted for therapeutic intervention. Reflex erection is achieved through direct stimulation of the penile shaft and is regulated by peripheral nerves and the lower segments of the spinal cord. On the other hand, psychogenic erection is elicited by erotic or emotional stimuli and relies on the brain's limbic system. The severity of erectile dysfunction is often classified as mild, moderate, or severe based on the results of the five-item International Index of Erectile Function (IIEF-5) questionnaire. Scores ranging from 1 to 7 indicate severe ED, 8 to 11 represent moderate ED, 12 to 16 indicate mild-moderate ED, 17 to 21 reflect mild ED, and 22 to 25 suggest no erectile dysfunction. The causes of ED can be categorized into two groups: those occurring alongside male hypoactive sexual desire disorder and those associated with normoactive sexual desire. Male hypoactive sexual desire disorder can result from diminished attraction towards a partner, psychogenic factors, or organic diseases. Normoactive sexual desire can be influenced by various conditions, including vasculogenic, cardiovascular, metabolic, neurological, inflammatory/infectious, mechanical, and iatrogenic factors. These pathogenic conditions contribute to a deficiency in vasodilating agents, particularly nitric oxide (NO), which is crucial for filling the corpora cavernosa. Various treatment options are available for erectile dysfunction. Initial treatment typically involves lifestyle modifications, followed by first-line therapies employing phosphodiesterase-5 (PDE5) inhibitors and vacuum erection devices (VEDs). Second-line therapies encompass the use of an intraurethral suppository (IUS) containing prostaglandin E1 (alprostadil) and intracavernosal injection (ICI) with vasoactive substances. Surgical intervention is considered a final resort after conservative approaches have been explored or attempted.

  • In the United States, the incidence of ED is 25.9 cases per 1000 people, and it increases with age, with more than 70% of men over 70 years old affected by ED.

Thelansis’s “Erectile Dysfunction (ED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erectile Dysfunction (ED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Erectile Dysfunction (ED) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Erectile Dysfunction (ED) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Erectile Dysfunction (ED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more